Yu. Yu. Mikhaleva

Yu. Yu. Mikhaleva

Auto-generated profile, based on publicly available information

Yu. Yu. Mikhaleva

A. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2022 in Koloproktologia
Verified
Journal Article
Open access
PDF file
ANA. A. Nevolskikh
A. A. Nevolskikh
VAV. A. Avdeenko
V. A. Avdeenko
ABA. S. Belohvostova
A. S. Belohvostova
RZR. F. Zibirov
R. F. Zibirov
YMYu. Yu. Mihaleva
Yu. Yu. Mihaleva
ЮМЮ. Ю. Михалёва
Ю. Ю. Михалёва
   Aim: to assess the effectiveness of neo-CT in the FOLFOX6 regimen in patients with mid- and upper rectal cancer (RC)associated with poor prognosis.  Patients and methods: fifty-two patients were included into study. All had neo-CT with subsequent surgical treat-ment between 2017 and 2021. Of them 94.2% had stage III and 5.8% had stage II. An extramural vascular invasionwas detected by MRI in 33 (63.5%) patients. The distance between the tumor and the mesorectal fascia was ≤ 2 mmin 17%. All patients had 4 cycles of neo-CT in FOLFOX6 regimen followed by surgery.   Results: the compliance (≥ 4 cycles of neo-CT) was 82.7 % (n = 43). The overall toxicity rate was 35.6 %. Sphincter-saving surgery was performed in 51 (98.1 %) patients. Postoperative morbidity was 25.0 %. Final pathology revealed stage III in 29 (55.8 %) patients, stage 0 — stage II — in 22 (42.3 %). In accordance with the degree of pathomorphosis (CAP, 2019), 12 (23.1 %) patients showed a partial response. In one patient (1.9 %) no signs of residual tumor were detected. Downstaging of the T stage compared with MRI data before neo-CT was noted in 23 (44.2 %) patients, N stage — in 29 (55.8 %). With a mean follow-up of 31 (3-54) months, local recurrences were detected in 5 (9.6 %) patients, and distant metastases in 4 (7.7 %). The cumulative 3-year recurrence rate was 11.3 ± 4.8 %. The three-year overall and recurrence-free survival rate was 88.2 ± 5.8 % and 76.4 ± 7.4 %, respectively.   Conclusion: the multimodal approach for RC with adverse prognostic factors using neo-CT in the FOLFOX6 regimenis well tolerated by patients, has a small toxicity and postoperative morbidity as well. It is necessary to develop newpathology criteria for tumor response to neo-CT.

5 September 2023 in Siberian journal of oncology
Verified
Journal Article
Closed access
ANA. A. Nevolskikh
A. A. Nevolskikh
YMY. Y. Mihaleva
Y. Y. Mihaleva
VAV. A. Avdeenko
V. A. Avdeenko
LTL. N. Titova
L. N. Titova
TBT. P. Berezovskaya
T. P. Berezovskaya
AKAndrei Kaprin
Andrei Kaprin
Introduction. The current standard of care is concurrent radiation therapy (RT) and chemotherapy with mitomycin or cisplatin in combination with fuoropyrimidine drugs. One possible option for effective chemotherapy regimens with a lower toxicity is the combination of oxaliplatin and capecitabine with RT. The purpose of the study: a retrospective evaluation of the results of combined treatment of 74 patients with squamous cell carcinoma of the anus (SCCA) with the use of oxaliplatin and capecitabine. Material and Methods. The study included 74 patients (men – 12.2 %, women – 87.8 %) with stage I–III SCCA. All patients underwent megavolt photon RT (2×25), a cumulative dose of 50 Gy and a boost of 10 Gy to the anal canal. From days 1 to 14 and from days 22 to 36 of RT, capecitabine was administered orally at a dose of 825 mg/m2 twice a day in combination with intravenous administration of oxaliplatin 50 mg/m2 on days 1, 8, 22, and 29 of RT. If a residual tumor 6 months after completion of chemoradiotherapy was found, patients underwent surgery. Results. All 74 patients underwent RT with a cumulative dose of 60 Gy. Chemotherapy, according to the protocol, was completed in 58 (78.4 %) patients. Grade 3-4 toxicity was noted in 11 (14.9 %) patients. In 64 patients (86.5 %), a complete clinical response was registered. At least one late radiation side effects according to the RTOG (LENT SOMA) scale was noted in 48 (98.0 %) patients, including grade 3-4 complications in 12 (24.5 %) patients. With a median follow-up of 40 months (3-82) cumulative three-year local recurrence rate, overall and relapse-free survival were 15.3 ± 4.5 %, 73.7 ± 5.7 % and 53.5 ± 6.4 %, respectively. Conclusion. Combined treatment of SCCA, based on the combination of RT with chemotherapy with oxaliplatin and capecitabine, is feasible and has acceptable acute toxicity. Additional clinical studies are needed using this chemotherapy regimen in combination with modern RT techniques.

25 November 2022 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ANAleksey A. Nevolskikh
Aleksey A. Nevolskikh
VAVioletta A. Avdeenko
Violetta A. Avdeenko
ABAnna S. Belokhvostova
Anna S. Belokhvostova
YMYuliya Yu. Mikhaleva
Yuliya Yu. Mikhaleva
TPTaras P. Pochuev
Taras P. Pochuev
МЮМихалева Юлия Юрьевна
Михалева Юлия Юрьевна
Rectal cancer (RC) is one of the leading tumor location in the structure of the incidence of malignant neoplasms in the Russian Federation and the world. And the standard approach to the treatment of patients with locally advanced forms of RC is preoperative chemo-radiotherapy (CRT) with delayed surgery. The use of such sort of approach in the recent decades has led to the reduction of the frequency of local recurrence up to 10% and even less. However, approximately a third of patients die of distant metastases. In this regard, one of the main tasks in the treatment of patients with locally advanced forms of RC with adverse prognostic factors is the prevention of distant metastasis formation. Early initiation of the systemic therapy before surgery is aimed at solving this issue. Conducting neoadjuvant chemotherapy (NCT) instead of CRT in RC treatment allows to avoid radiation reactions and injuries, occurring in some patients. Two-component oxaliplatin-containing regimens are the most well studied types of NCT in the treatment of patients with non-metastatic RC. In this connection, despite the differences in the treatment regimens and the number of cycles, a good tolerability of the method as well as no effect on the frequency of postoperative complications and in general a satisfactory results comparable to the effects of CRT were observed. The use of NCT in combination with targeted treatment modalities as well as three-component chemotherapy regimens are promising and encouraging treatment options for patients with RC with adverse prognostic factors.

27 February 2024 in Koloproktologia
Verified
Journal Article
Open access
PDF file
АНА. А. Невольских
А. А. Невольских
ABA. R. Brodskiy
A. R. Brodskiy
VAV. A. Avdeenko
V. A. Avdeenko
TPT. P. Pochuev
T. P. Pochuev
YMYu. Yu. Mihaleva
Yu. Yu. Mihaleva
ЮМЮ. Ю. Михалева
Ю. Ю. Михалева
Трансанальные эндомикрохирургические вмешательства при раке прямой кишки после лучевой или химиолучевой терапии — нюансы и результаты

4 March 2024 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
ANA. A. Nevolskikh
A. A. Nevolskikh
VAV. A. Avdeenko
V. A. Avdeenko
YMYu. Yu. Mikhaleva
Yu. Yu. Mikhaleva
TPT. P. Pochuev
T. P. Pochuev
PSP. V. Sokolov
P. V. Sokolov
ЮМЮ. Ю. Михалева
Ю. Ю. Михалева
Introduction. The standard volume of removed groups of lymph nodes for right colon cancer (RCC) has not been determined. According to Japanese clinical guidelines, it is necessary to perform D3 lymphadenectomy in all cases, except stage I, while according to European and Russian clinical guidelines, the standard scope of surgical intervention includes only D2 lymphadenectomy. There are no long-term results regarding differences between D2 and D3 lymph node dissection in RCC; therefore, it is relevant to conduct studies to improve the long-term results of treatment of patients with RCC.Aim: to comparatively evaluate the results of treatment of patients with RCC who underwent laparoscopic right hemicolectomy at A. Tsyb Medical Radiological Research Center.Materials and methods. Conducted from 2018 to 2023, the study included 174 patients with stage I–III RCC: in 106 patients, laparoscopic right hemicolectomy with D2 lymph node dissection was performed, in 68 patients — with D3 lymph node dissection. When assessing the homogeneity and comparability of the groups, according to input parameters, such as clinical stage, gender, age, body mass index and tumor location, their heterogeneity was noted, which did not allow a direct comparative assessment of both groups. To eliminate heterogeneity and adequately select groups, a pseudorandomization technique was used, after which the groups (n = 68) became statistically comparable in all main clinical parameters.Results. Statistically significant differences were obtained in the median duration of surgical intervention, which was longer in the group of patients with D3 lymph node dissection — 150 (60–393) and 213 (70–390) minutes (p < 0.001), and in the median time of flatus passage — 2 (1–4) and 3 (1–9) days, respectively (p = 0.042). Postoperative complications in accordance with the Clavien — Dindo classification occurred in 16 (23.5 %) patients in the group with D2 and in 15 patients (22.1 %) in the group with D3 lymph node dissection (p = 0.999); III–V grade complications were noted in 2 (2.9 %) cases in each group (p = 0.999). Postoperative hospital stay was 6 days for patients in both groups (p = 0.369). During pathomorphological assessment of the removed specimen, the median number of examined lymph nodes was significantly higher in the group with D3 lymph node dissection: 14 (1–52) and 19 (3–59) lymph nodes, respectively (p < 0.001). Involvement of apical lymph nodes (groups 203, 213, 223) was noted in 2 (3 %) patients. In the group with D2 lymph node dissection, distant metastases were recorded twice as often as in the group with D3 lymph node dissection — in 8 (11.8 %) and 4 (5.9 %) patients, respectively (p = 0.365). Local recurrence was not established in any case. The three-year overall and disease-free survival rates were 94.8 ± 3.0 and 100 % (p = 0.149) and 80.5 ± 5.8 and 88.7 ± 5.8 % (p = 0.177), respectively.Conclusions. The experience of using total mesocolonectomy with D3 lymph node dissection for RCC indicates the safety of this surgical intervention in comparison with traditional surgical techniques, while we did not obtain statistically significant differences in patient survival. To definitively determine the role of D3 lymph node dissection in the treatment of patients with RCC, large multicenter randomized studies are certainly needed.

16 August 2025 in Koloproktologia
Verified
Journal Article
Open access
PDF file
ANA. A. Nevolskikh
A. A. Nevolskikh
VAV. A. Avdeenko
V. A. Avdeenko
TBT. P. Berezovskaya
T. P. Berezovskaya
TPT. P. Pochuev
T. P. Pochuev
YDYa. A. Daineko
Ya. A. Daineko
ЮМЮ. Ю. Михалёва
Ю. Ю. Михалёва
AIM: to determine the algorithm for selecting patients included in the ASP program after prolonged chemoradiotherapy (CRT) with consolidation chemotherapy (CCT).PATIENTS AND METHODS: the retrospective study included patients with adenocarcinoma of the low and middle rectum (2017 to 2024), who achieved cCR after CRT with CCT, which led to the decision to implement ASP. Radiotherapy was administered in a prolonged mode at a dose of 50–55 Gy with oral capecitabine intake. Between the completion of CRT and the first follow-up examination, 4 cycles of CCT were done in the FOLFOX6 regimen. Clinical tumor regression was assessed 4 weeks after the completion of CCT, based on the data from endoscopy, digital examination, and MRI. cCR was understood to refer to cases where, during endoscopic treatment performed after CRT and CCT at the site of the previously determined tumor, there were signs of a flat white/red scar.RESULTS: the study included 27 patients (15 (55.6%) men, 12 (44.4%) women). The patients' age ranged from 38 to 80 years (median 63 years). The median distance from the anal verge to the lower edge of the tumor was 4.5 (2.0–9.5) cm. Most patients had clinical stage III disease — 18/27 (66.7%), while the tumor size in the largest dimension ranged from 2.4 to 6.5 cm (median 4.0 cm). The median interval between the completion of CRT and the follow-up examination was 16 (9–25) weeks. MRI of the pelvic organs revealed TRG1 in 13/27 (48.1%) patients, TRG2 also in 13/27 (48.1%) and in one patient (3.7%) has a mucinous tumor that is not subject to standard TRG assessment. The MRI findings of all patients selected for ASP was characterized by fibrosis of the tumor bed without signs of residual tumor tissue/affected lymph nodes in the mesorectal tissue and deep layers of the wall, while both thin and full-thickness and split fibrous scars present, extending up to half the circumference. All patients who achieved cCR had a primary tumor of category up to T3b inclusive. With a median follow-up of 14.7 (3.8–80.2) months, tumor regrowth was observed in 2/27 patients (7.4%), both of whom underwent radical surgeries. Three-year relapse-free survival rate was 81.1 ± 10.1%, while overall survival 95.2 ± 4.6%.CONCLUSIONS: the implementation of an ASP program after CRT should be based on careful selection of patients who have achieved cCR according to comprehensive check-up. It is advisable to begin the examination with MRI followed by endoscopy, as this approach provides all necessary information and avoids artifacts in MRI that may arise after endoscopy. Endoscopy plays a leading role in assessing the intraluminal tumor component, with the only manifestation of cCR being a flat white or red scar.